Lund, Sweden — 30 April 2025 — Camurus (CAMX) today announces that the Annual Report for 2024 now is available at the company's website: www.camurus.com, and as an attachment to this press release. The Swedish version of the Annual Report is also available on the website in European Single Electronic Format (ESEF).
The Annual Report also includes Camurus’ sustainability report.
Fredrik Tiberg, President and CEO:
“Camurus had an excellent year with high growth and profitability, strong performances across the business, and progress in our R&D pipeline. Buvidal® continued to grow well and is now the treatment of choice for opioid dependence in several markets in Europe and Australia. In addition, the US roll-out of Brixadi® by Braeburn continued to progress. On the product development side, we received positive Phase 3 results from the long-term ACROINNOVA 2 study of CAM2029 for the treatment of acromegaly, although the expected FDA approval was delayed due to observations during an inspection at a third-party manufacturer. Apart from acromegaly, two clinical studies of CAM2029 progressed in patients with neuroendocrine tumors and polycystic liver disease, and a new clinical study evaluating our once-monthly semaglutide depot (CAM2056) was initiated in participants with overweight or obesity.”
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
[email protected]
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
[email protected]
About Camurus
Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn.
This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 10:00 am CET on 30 April 2025.